Teladoc Health, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 15. Exhibits and Financial Statement Schedules
(a) (1)Our consolidated financial statements are listed in the Index to Consolidated Financial Statements and Supplemental Data filed as part of this Annual Report on Form 10-K.
(2)Schedule II—Valuation and Qualifying Accounts.
Valuation and Qualifying Accounts (in thousands):
| Descriptions | Balance atBeginningof Period | Provision | Other | Write-offs | Balance atEnd of Period |
|---|---|---|---|---|---|
| Allowance for Doubtful Accounts | |||||
| 2025 (1) | $5,134 | $1 | $857 | $(1,959) | $4,033 |
| 2024 | $4,240 | $3,795 | $(23) | $(2,878) | $5,134 |
| 2023 | $4,324 | $4,686 | $3,001 | $(7,771) | $4,240 |
| Income Tax Valuation Allowance | |||||
| 2025 (1) | $416,701 | $29,385 | $7,337 | $— | $453,423 |
| 2024 (2) | $418,234 | $(275) | $(1,258) | $— | $416,701 |
| 2023 (2) | $415,751 | $1,904 | $579 | $— | $418,234 |
(1)Other includes currency translation adjustments as well as purchase accounting and acquisition-related adjustments for 2025.
(2)Other reflects currency translation adjustments.
(3)A list of exhibits is set forth on the Exhibit Index immediately prior to the signature page of this Annual Report on Form 10-K, and is incorporated herein by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.